Sequoia-Tata Capital deal for Sai Life comes unstuck?
This article was originally published in Scrip
Venture capital firm Sequoia's deal with Tata Capital, through which the former was said to be eyeing an exit from the Indian contract research organization (CRO), Sai Life Sciences, may have fallen through, if pharma industry and investment banking experts are to be believed.
You may also be interested in...
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.